Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Harmony Biosciences Holdings, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/11/2023 8-K Quarterly results
10/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
08/14/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC."
08/01/2023 8-K Quarterly results
07/27/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financi...
05/26/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/02/2023 8-K Quarterly results
04/24/2023 8-K Quarterly results
03/29/2023 8-K Quarterly results
03/10/2023 8-K Other Events  Interactive Data
01/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "HARMONY BIOSCIENCES APPOINTS JEFFREY DAYNO, MD AS INTERIM CEO AND EXPANDS ROLE OF JEFF ARONIN TO EXECUTIVE CHAIRMAN"
10/03/2022 8-K Other Events  Interactive Data
08/02/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/03/2022 8-K Investor presentation, Quarterly results
02/28/2022 8-K Quarterly results
11/22/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/09/2021 8-K Investor presentation, Quarterly results
08/10/2021 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Transcript of Conference Call held by the Company on August 10, 2021",
"Investor Presentation"
06/15/2021 8-K Quarterly results
05/21/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
02/19/2021 8-K Quarterly results
12/17/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : December 17, 2020 HARMONY BIOSCIENCES HOLDINGS, INC. Delaware 001-39450 82-2279923 630 W. Germantown Pike, Suite 215 Plymouth Meeting, PA 19462 539-9800 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant...",
"HARMONY BIOSCIENCES TO BE ADDED TO RUSSELL 2000 ® AND RUSSELL 3000 ® INDEXES"
12/15/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : December 15, 2020 HARMONY BIOSCIENCES HOLDINGS, INC. Delaware 001-39450 82-2279923 630 W. Germantown Pike, Suite 215 Plymouth Meeting, PA 19462 539-9800 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant...",
"HARMONY BIOSCIENCES ENROLLS FIRST PATIENT IN PHASE 2 TRIAL EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH PRADER-WILLI SYNDROME"
11/12/2020 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : November 12, 2020 HARMONY BIOSCIENCES HOLDINGS, INC. Delaware 001-39450 82-2279923 630 W. Germantown Pike, Suite 215 Plymouth Meeting, PA 19462 539-9800 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant...",
"HARMONY BIOSCIENCES REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND BUSINESS UPDATES",
"Investor Presentation"
11/12/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "HARMONY BIOSCIENCES APPOINTS MARK GRAF AND ERIC MOTLEY TO ITS BOARD OF DIRECTORS"
10/14/2020 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Regulation...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : October 13, 2020 HARMONY BIOSCIENCES HOLDINGS, INC. Delaware 001-39450 82-2279923 630 W. Germantown Pike, Suite 215 Plymouth Meeting, PA 19462 539-9800 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant ...",
"HARMONY BIOSCIENCES RECEIVES FDA APPROVAL FOR EXPANDED USE OF WAKIX ® FOR THE TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NARCOLEPSY"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy